NASDAQ · GRCE
Grace Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GRCE: Nov 12, 2026
Grace Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.15.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Quiver Quantitative- BNK Invest · Sep 10, 2:48 PM EDTThursday 9/10 Insider Buying Report: SEI, GRCEAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Tuesday, Solaris Energy Infrastructure's Director, AJ Teague, made a $500,994 pu
- RTTNews · Aug 5, 5:37 AM EDTGrace Enters $10 Mln Private Placement; Initiates Second Manufacturing Pathway For GTx-104; Stock Up(RTTNews) – Grace Therapeutics, Inc. (GRCE), a clinical-stage biopharma company, announced on Wednesday that it has entered into a securities purchase agreement for a private placement financing with investors, with gross proceeds from the private placement expected to be $10 mil
- RTTNews · Jun 22, 6:22 AM EDTGrace Records Net Loss Of $7 Mln In FY26; To Resubmit NDA For GTx-104 In Subarachnoid Hemorrhages(RTTNews) – Grace Therapeutics Inc. (GRCE), a late-stage biopharmaceutical company, on Thursday announced financial results for the fiscal year ending March 31, 2026, and provided updates on the NDA resubmission for GTx-104 in treating aneurysmal subarachnoid hemorrhages.
- RTTNews · Apr 24, 10:34 AM EDTWeekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovarian cancer and stiff person syndrome.
- RTTNews · Apr 24, 2:21 AM EDTFDA Issues CRL To Grace Therapeutics For GTx-104 In ASAH; Stock Down(RTTNews) – Grace Therapeutics, Inc. (GRCE) announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the firm's New Drug Application (NDA) for GTx-104 for the treatment of patients with aneurysmal Subarachnoid Haemorrhage or aSAH.
- RTTNews · Nov 3, 11:58 PM ESTBiotech Earnings Spark After-Hours Surge: TCMD, BDSX, EXAS Lead The Charge(RTTNews) – Several biotech stocks rallied after hours Monday, fueled by strong Q3 earnings and upgraded full-year guidance. Here's a quick look at the biggest movers and their catalysts.
- RTTNews · Aug 27, 8:34 AM EDTGrace Therapeutics: FDA To Review NDA For GTx-104(RTTNews) – Grace Therapeutics (GRCE) announced that on August 22, 2025 the FDA accepted the New Drug Application for GTx-104 for formal review. The application seeks approval for GTx-104 for the treatment of patients with aSAH. The FDA established a PDUFA target date of April 23
- Quiver Quantitative · Jun 22, 5:05 PM EDTGRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and MoreGRACE THERAPEUTICS ($GRCE) is expected to release its quarterly earnings data on Tuesday, June 24th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.32 per share.
- Quiver Quantitative · Jun 13, 8:13 AM EDTGrace Therapeutics CEO Prashant Kohli to Attend BIO 2025 International Conference in BostonGrace Therapeutics' CEO will attend BIO 2025 International Conference to discuss GTx-104 for aneurysmal subarachnoid hemorrhage.
- RTTNews · Feb 14, 7:41 AM ESTGrace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage(RTTNews) – Grace Therapeutics (GRCE), a late-stage biopharmaceutical company, on Thursday, announced financial results and business highlights for the quarter ended December 31, 2024.
- Quiver Quantitative · Feb 13, 3:55 PM ESTGRACE THERAPEUTICS Earnings Results: $GRCE Reports Quarterly EarningsGRACE THERAPEUTICS ($GRCE) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of -$0.26 per share, beating estimates of -$0.44 by $0.18. The company also reported revenue of $0, equaling estimates of $0 by $0.
- Quiver Quantitative · Feb 13, 8:13 AM ESTGrace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025Grace Therapeutics announced positive Phase 3 trial results for GTx-104, securing $30 million in funding and plans for NDA submission.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Grace Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.